Henan Center for Disease Control and Prevention, Zhengzhou 450016, PR China.
Eur J Cancer. 2010 Mar;46(4):758-64. doi: 10.1016/j.ejca.2009.12.010. Epub 2009 Dec 22.
Genetic variations in metabolic genes are thought to modify the metabolic process of carcinogens and are suggested to be related to cancer risk. However, epidemiological results are not always consistent. In this meta-analysis, we assessed reported studies of associations between polymorphisms of CYP2E1 RsaI/PstI and DraI, and the risk of lung cancer. We found decreased lung cancer risk among subjects carrying CYP2E1 RsaI/PstI c1/c2 and c1/c2+c2/c2 genotype [odds ratio (OR)=0.80, 95% confidence interval (CI): 0.72-0.89 and OR=0.82, 95% CI: 0.72-0.93, respectively], using 4436 cases and 6385 controls from 26 studies. We also observed a decreased lung cancer risk among subjects carrying c1/c2 and c1/c2+c2/c2 genotypes in the Asian population and on the basis of population control in stratified analysis. We found a protective effect of the CYP2E1 DraI CC and CD+CC polymorphisms for lung cancer (OR=0.58, 95% CI: 0.41-0.81 and OR=0.84, 95% CI: 0.73-0.96, respectively). The meta-analysis suggests that CYP2E1 RsaI/PstI and DraI polymorphisms may affect the susceptibility of lung cancer, and a study with a larger sample size is needed to further evaluate gene-environment interaction on CYP2E1 polymorphisms and lung cancer risk.
遗传变异在代谢基因中被认为可以修饰致癌物的代谢过程，并与癌症风险有关。然而，流行病学结果并不总是一致的。在这项荟萃分析中，我们评估了 CYP2E1 RsaI/PstI 和 DraI 多态性与肺癌风险之间关联的报告研究。我们发现，携带 CYP2E1 RsaI/PstI c1/c2 和 c1/c2+c2/c2 基因型的受试者患肺癌的风险降低[比值比（OR）=0.80，95%置信区间（CI）：0.72-0.89 和 OR=0.82，95% CI：0.72-0.93，分别]，使用了来自 26 项研究的 4436 例病例和 6385 例对照。我们还观察到，在亚洲人群和分层分析中的人群对照中，携带 c1/c2 和 c1/c2+c2/c2 基因型的受试者患肺癌的风险降低。我们发现 CYP2E1 DraI CC 和 CD+CC 多态性对肺癌具有保护作用（OR=0.58，95% CI：0.41-0.81 和 OR=0.84，95% CI：0.73-0.96，分别）。荟萃分析表明，CYP2E1 RsaI/PstI 和 DraI 多态性可能影响肺癌的易感性，需要更大的样本量研究来进一步评估 CYP2E1 多态性与肺癌风险的基因-环境相互作用。
